Studies Two Proteins Involved in Mesothelioma Growth and Spread
Observes how the proteins HMGB1 and CXCR4 act in mesothelioma.
Plain-language title generated from the registry record
Registry title: New Preclinical and Clinical Approaches to Mesothelioma
Key facts
- Where
- Milan and Naples, ItalySee the 2 sites
Where in Italy
- IRCCS San RaffaeleMilan, ItalyTaking people
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Naples, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Marco Emilio Bianchi
- Trial code
- NCT06536179
- Record updated
- 2 August 2024
- Original description
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.Read full original descriptionShow less
New Preclinical and Clinical Approaches to Mesothelioma, an Archetypal Inflammatory Tumor
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
Inclusion: Patients with Mesothelioma:; Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma; Candidates for surgical intervention; Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women; Capacity to comprehend the study nature and provide autonomously informed consent; Control Group patients:; Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious); Candidates for surgical intervention; Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women; Ability to understand the study nature and provide autonomously informed consent; If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study.
Exclusion: Lack of biopsy material; pregnancy; Unwillingness to sign the Informed Consent.